156. Rett syndrome
36 clinical trials,   49 drugs   (DrugBank: 19 drugs),   77 drug target genes,   112 drug target pathways

Searched query = "Rett syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03059160
(ClinicalTrials.gov)
April 1, 20172/2/2017Open Label Trial of Triheptanoin (UX007) in Treatment of Rett Syndrome.Open Label Trial of Triheptanoin (UX007) in Treatment of Rett Syndrome.Rett SyndromeDrug: Tridecanoic AcidSheba Medical CenterUltragenyx Pharmaceutical IncNot yet recruiting5 Years18 YearsFemale10Phase 2NULL
2NCT02696044
(ClinicalTrials.gov)
June 201625/2/2016Treatment of Mitochondrial Dysfunction in Rett Syndrome With TriheptanoinTreatment of Mitochondrial Dysfunction in Rett Syndrome With Triheptanoin: An Open-label, 10-subject Clinical Trial of UX007 (Triheptanoin) in the Treatment of Mitochondrial Dysfunction in Participants With Rett Syndrome, Dyskinesia, and EpilepsyRett SyndromeDrug: triheptanoinCenter for Rare Neurological Diseases, Norcross, GAUltragenyx Pharmaceutical Inc;Rett Syndrome Research TrustRecruiting2 YearsN/AFemale12Phase 2United States